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We recently developed a new assay to measure proteasome
activity in vitro (CAPA for capture proteasome assay) [1], based on
proteasome capture on an antibody-coated plate. When used with
lysates originating from cells expressing either standard protea-
some, immunoproteasome or intermediate proteasomes β5i or
β1i-β5i, this assay allows the individual monitoring of the
chymotrypsin-like, trypsin-like and caspase-like activities of the
corresponding proteasome subtypes. The efﬁciency and speciﬁcity
of four proteasome inhibitors were studied using the CAPA assay,
demonstrating the potential of this assay for the development of
subtype-speciﬁc proteasome inhibitors.
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
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ke activities, respectivelyFluorescence microplate readerData format Analyzed
Experimental factors Not applicable
Experimental features Proteasomes are captured on a microplate and ﬂuorogenic peptides are used to measure proteasome
activity in vitro
Data source location Not applicable
Data accessibility Not applicableValue of the data Measure of proteasome activity based on a single step of proteasome antibody capture.
 Bypasses the heavy and complex procedures of proteasome puriﬁcation.
 Eliminates the need of using protease inhibitors for result interpretation.
 Useful for the identiﬁcation of proteasome subtype-speciﬁc inhibitors.
 Assay performed in the absence of MgSO4, which affects proteasome function.1. Data, experimental design, materials and methods
1.1. Data
To facilitate the in vitro study of proteasome activity, we have designed a new type of assay (CAPA
for capture proteasome assay) based on the speciﬁc capture of proteasomes on 96-well plates [1]
(Fig. 1). Using this assay, proteasomes contained in any type of human cell lysate are captured on a
black Maxisorp plate pre-coated with the anti-proteasome α2 subunit antibody MCP21 and tested for
their ability to degrade ﬂuorogenic peptides suc-LLVY-AMC, Z-LLE-AMC or Boc-LRR-AMC. This enablesCell lysate: 293 cell expressing either
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.
N. Vigneron et al. / Data in Brief 4 (2015) 146–151148the measurement of the chymotrypsin-like, caspase-like and trypsin-like activities of the proteasome,
respectively (Fig. 1). Applying the CAPA assay to lysates from cells expressing either standard
proteasome (SP), immunoproteasome (IP) or intermediate proteasomes β5i (SIP) or β1i-β5i (DIP) [2],
we could monitor the activity of each proteasome subtype [1]. As shown in Fig. 2, ﬂuorescence
emission follows a linear slope over time, thereby enabling the quantitative measurement of
proteasome activity up to at least four hours after addition of the substrate. The development of
subtype-speciﬁc proteasome inhibitors is the focus of intensive investigations in the ﬁeld of anti-
cancer therapy as well as inﬂammation-related autoimmune diseases. In that regard, the CAPA assay,
coupled to the use of the 293-EBNA cell lines expressing either proteasome type represents a tool of
choice to facilitate the study of proteasome subtype inhibitors. As a proof-of-concept, we have used
the CAPA assay to test the effect of four different proteasome inhibitors (bortezomib, lactacystin,
epoxomicin and PR-957) on the chymotrypsin-like, caspase-like and trypsin-like activities of the four
proteasome subtypes (see Figure 7 and 8 in Ref [1]). The mean of the IC50 values measured for each
inhibitor on a given proteasome subtype are reported in Table 1. To illustrate the robustness of the
CAPA assay for measuring proteasome inhibition in vitro, Fig. 3 displays the different IC50 values
measured in a series of independent experiments. Our results show that the dipeptide boronic acid
bortezomib blocked the chymotrypsin-like activity and caspase-like activity with IC50 values of
15 nM for the chymotrypsin-like activity and 40 nM for the caspase-like activity (Figure 7A in Ref
[1], Table 1 and Fig. 3). Bortezomib was effective at blocking the chymotrypsin-like activities of the
four types of proteasomes, showing that it targets equally β5 or β5i. As expected, the concentration ofTime (min)
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Fig. 2. Kinetics of AMC release during the CAPA assay over time. Lysates from 293 cells expressing immunoproteasome (A,C) or
standard proteasome (B) were loaded on a 96-well black Maxisorp plate pre-coated with the anti-α2 MCP21 antibody.
Following proteasome capture, the plate was carefully washed and proteasome activity was measured using the substrates Suc-
LLVY-AMC, Z-LLE-AMC or Boc-LRR-AMC, which are speciﬁc for the chymotrypsin-like, caspase-like and trypsin-like activities,
respectively. After addition of the ﬂuorogenic substrates, AMC release (7SD) was recorded over time at 37 1C either for short
time intervals (upper graphs) or longer time intervals (lower graphs).
Table 1
IC50 of the four proteasome inhibitors, measured in the CAPA assay. Statistical signiﬁcance of the difference between the IC50
measured for each proteasome subtype and the IC50 measured for the standard proteasome is indicated in upper case. ANOVA
with Bonferroni's multiple comparison test.
Inhibitor Standard Proteasome
IC50 (7SEM) nM
Intermediate Proteasome
β5i IC50 (7SEM) nM
Intermediate Proteasome β1i
β5i IC50 (7SEM) nM
Immunoproteasome
IC50 (7SEM) nM
Chymotrypsin-like activity
Bortezomib
(n¼7)
20 (74) 14 (72)ns 15 (72)ns 17 (73)ns
Lactacystin
(n¼7)
279 (782) 2165 (7476)nn 2357 (7599)nn 2841 (7765)nnn
Epoxomicin
(n¼7)
21 (79) 207 (786)ns 260 (7105) ns 388 (7138)nn
PR-957
(n¼5)
618 (7121) 69 (731)nnnn 48 (717)nnnn 70 (729)nnnn
Caspase-like activity
Bortezomib
(n¼4)
48 (77) 41 (77)ns n.d. n.d.
Lactacystin
(n¼3)
45000 45000 n.d. n.d.
Epoxomicin
(n¼3)
41000 41000 n.d. n.d.
PR-957
(n¼3)
45000 45000 n.d. n.d.
Trypsin-like activity
Bortezomib
(n¼6)
1605 (7291) 1729 (7313) 1095 (7214) 653 (7127)
Lactacystin
(n¼3)
45000 45000 45000 45000
Epoxomicin
(n¼4)
41000 41000 41000 41000
PR-957
(n¼4)
45000 45000 45000 45000
ns: not signiﬁcant.
nn pr0.01.
nnn pr0.001.
nnnn pr0.0001.
N. Vigneron et al. / Data in Brief 4 (2015) 146–151 149lactacystin required to block the chymotrypsin-like activity of the proteasome was much lower than
that necessary to block the caspase-like and trypsin-like activities (Figure 7B in Ref [1], Table 1 and
Fig. 3). Interestingly, lactacystin inhibited more effectively the chymotrypsin-like activity of the SP,
suggesting that it targets more efﬁciently the β5 subunit than the β5i subunit. Similar results were
obtained with epoxomicin (Figure 8A in Ref [1], Table 1 and Fig. 3). Proteasome inhibitor PR-957,
which is known to speciﬁcally target β5i, efﬁciently blocked the chymotrypsin-like activity of the IP,
the SIP and the DIP, while being much less efﬁcient at inhibiting the chymotrypsin-like activity of the
SP (Figure 8B in Ref [1], Table 1 and Fig. 3). PR-957 was not effective on the caspase-like and trypsin-
like activities of the proteasomes. Overall these results show the potential of the CAPA assay for the
study and identiﬁcation of proteasome subtype-speciﬁc inhibitors.
1.2. Experimental design and methods
1.2.1. Cell lines
293 cells expressing the standard proteasome (β1-β2-β5), the immunoproteasome (β1i-β2i-β5i), the
intermediate proteasome β5i (SIP) or β1i-β5i (DIP) [2] were grown in Iscove's Modiﬁed Dulbecco's
Medium (IMDM, Thermo Scientiﬁc Inc., Waltham, MA, USA) containing 10% fetal calf serum (Thermo
Scientiﬁc) and supplemented with Puromycin (5 mg/ml, Sigma, St Louis, MA, USA) and/or Hygromycin
(600 mg/ml, InvivoGen, San Diego, CA, USA). All culture media were supplemented with L-arginine
IC
50
 B
or
te
zo
m
ib
 (n
M
)
10-2
100
102
104
106
Chymotrypsin-like  
SP SIP DIP IP
IC
50
 L
ac
ta
cy
st
in
 (n
M
)
Chymotrypsin-like  
100
102
104
106
SP SIP DIP IP
IC
50
 E
po
xo
m
ic
in
 (n
M
)
Chymotrypsin-like  
100
102
104
106
SP SIP DIP IP
IC
50
 P
R
-9
57
 (n
M
)
Chymotrypsin-like  
100
102
104
106
SP SIP DIP IP
IC
50
 B
or
te
zo
m
ib
 (n
M
)
Trypsin-like  
10-2
100
102
10  4
106
SP SIP DIP IP
IC
50
 B
or
te
zo
m
ib
 (n
M
)
Caspase-like  
10-2
100
102
104
106
SP SIP
10-2
10-2
10-2
Fig. 3. Reproducibility of IC50 determination for the four proteasome inhibitors. Lysates from 293 cells expressing standard
proteasome (SP), immunoproteasome (IP) or intermediate proteasomes β5i (SIP) or β1i-β5i (DIP) were loaded on a 96-well black
Maxisorp plate pre-coated with the anti-α2 antibody MCP21. Following proteasome capture, the plate was carefully washed and
the proteasome inhibitor was added at different concentrations. Proteasome activity was then measured using the substrates
Suc-LLVY-AMC, Z-LLE-AMC or Boc-LRR-AMC, which are speciﬁc for the chymotrypsin-like, caspase-like and trypsin-like
activities, respectively. Each symbol represents the IC50 measured in one experiment performed in duplicates. Lines indicate
means 7 SEM.
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N. Vigneron et al. / Data in Brief 4 (2015) 146–151 151(116 mg/l), L-asparagine (36 mg/l), L-glutamine (216 mg/l), penicillin (100 U/ml) and streptomycin
(100 mg/ml) (Thermo Scientiﬁc). The MCP21 hybridoma was obtained from ECACC and the antibody
was puriﬁed from hybridoma supernatant using HiTrap Columns Prepacked with Protein G Sepharose [3].
1.2.2. Capture proteasome assay (CAPA)
Black 96-well maxisorp plates (VWR, Radnor, PA, USA) were coated using 5 mg/ml MCP21 antibody
and then further blocked for 1 h in PBS containing 2% BSA. Cell pellets were washed in PBS and lysed
on ice at a cell density of 107 cells/ml in TRIS 50 mM NP40 0.1% pH 7.5. Post nuclear supernatant is
then collected, analyzed using the BCA protein assay kit (Thermo Scientiﬁc) and adjusted to a
concentration of 200 mg per ml in lysis buffer (Tris 50 mM NP40 0.1% pH 7.5). 50 ml of cell lysate is
then added in each well and the plates were incubated for 2 h at 4 1C. The amount of proteasome
captured in these conditions was estimated to be around 200 ng per well using quantitative ELISA [2].
After proteasome capture, plates were carefully washed in Tris 20 mM NP40 0.1% pH 7.5 then in Tris
20 mM pH 7.5 to remove traces of detergent. Proteasome inhibitors diluted in Tris 20 mM pH 7.5 were
then added to the wells and incubated under rotation for 10 min at room temperature. Finally,
ﬂuorogenic substrates Suc-LLVY-AMC, Z-LLE-AMC or Boc-LRR-AMC (Enzo, Farmingdale, NY, USA) were
added to the wells at a concentration of 100 mM in Tris 20 mM. Plates were then sealed with a plastic
cover and incubated at 37 1C for about 30 min. Fluorescence emission was then measured using the
proteasome-GloMAX apparatus (Promega, Fitchburg, WS, USA) or the SpectraMax 190 Microplate
Reader (Excitation 380 nm, Emission 460 nm). The linearity of ﬂuorescence emission over time is
veriﬁed by performing measurements at different time points as shown in Fig. 2. The IC50 values were
calculated in Prism 5.0 (Graphpad, San Diego, CA, USA) from a log (inhibitor) vs response curve
(variable slope) using the equation Y¼Bottomþ(Top-Bottom)/(1þ10((Log IC50-X)nHillSlope)) where X is
the logarithm of the inhibitor concentration and Y the proteasome activity.Acknowledgements
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